Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON21037
NL-OMON21037
Recruiting
Not Applicable

A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody for the lntraoperative Detection of Neoplastic Lesions in Patients with Cancer of the Rectum or Pancreas

eiden University Medical Center (LUMC) and Centre for Human Drug Research (CHDR), Leiden, the Netherlands0 sites30 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsrectal cancerpancreatic cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
rectal cancerpancreatic cancer
Sponsor
eiden University Medical Center (LUMC) and Centre for Human Drug Research (CHDR), Leiden, the Netherlands
Enrollment
30
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
eiden University Medical Center (LUMC) and Centre for Human Drug Research (CHDR), Leiden, the Netherlands

Eligibility Criteria

Inclusion Criteria

  • •1\. Patients aged over 18 years old;
  • •2\. Patient should be scheduled and eligible for surgery because of a clinical diagnosis of cancer of the
  • •rectum or cancer of the pancreas;

Exclusion Criteria

  • •1\. Anticancer therapy (e.g. chemotherapy, radiotherapy(except routine pre\-operative radiotherapy for
  • •rectal cancer), targeted therapy, concomitant systemic immune therapy, or any experimental therapy)
  • •within 4 weeks before inclusion;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Neoplastic Lesions in Patients with Cancer of the Colorectum or Pancreas
NL-OMON47359Surgimab85
Completed
Not Applicable
A phase I study assessing the safety and performance of VB5-845D-800CW, an anti-Epcam fluorescent agent, for the intraoperative detection of gastrointestinal canceresophageal/gastric- or colorectal cancer10017990
NL-OMON48830eids Universitair Medisch Centrum34
Recruiting
Phase 1
Phase I study of MTC001 in patients with chronic ischemic heart failure
JPRN-jRCT2033210078Machino Takeshi6
Withdrawn
Phase 1
A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.PART 3.MalariaInfection - Other infectious diseases
ACTRN12613000533796CPR Pharma Services24
Completed
Phase 1
A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.PART 1.
ACTRN12613000522718CPR Pharma Services73